Home | Sitemap | Contact Us     Search Ranbaxy for  
  Quick Links
 
 
   
   
 
    
 
     
 
   
 
 


Home
Investor Relations > Financials > P & L Account > Ranbaxy Laboratories Limited - Consolidated (US GAAP)
 

     P & L Account


Untitled Document

   
CONSOLIDATED STATEMENTS OF INCOME
(All amounts in Rupees Million, unless otherwise stated)
 
Year ended December 31,
 
2006
2005
Revenues
Product sales
60,275.71
50,468.67
Service income
406.47
273.75
Other operating revenue
738.11
856.11
 
61,420.29
51,598.53
Cost of sales (excluding depreciation and amortization)
29,465.74
27,143.85
Gross profit
31,954.55
24,454.68
Operating expenses
  Selling, general and administrative expenses
19,651.83
17,274.06
  Research and development expenses
3,982.42
5,055.33
  Depreciation and amortization
2,894.31
1,718.00
  Foreign exchange (gain) / loss (682.06) 978.98
Total operating expenses
25,846.50
25,026.37
Operating income / (loss)
6,108.05
(571.69)
Equity in gain of affiliate
50.30
4.71
Interest expense
(1,789.20)
(669.60)
Interest income
207.05
173.99
Other income
431.28
300.49
Income / (loss) from continuing operations before income taxes, discontinued operations and minority interest
5,007.48
(762.10)
Income tax expense / (benefit) on continuing operations
889.58
(1,020.91)
Income from continuing operations before discontinued operation and minority interest
4,117.90
258.81
Minority interest
(57.31)
(26.38)
Income from continuing operations
4,060.59
232.43
Gain on disposal of discontinued operations, net of tax
-
161.88
Income from discontinued operations, net of tax
-
384.72
Net income
4,060.59
779.03
Earnings per equity share
Basic
  Continuing operations
Rs. 10.90
Rs. 0.62
  Discontinued operations
Rs. 1.47
Net income Rs. 10.90 Rs. 2.09
Diluted    
  Continuing operations Rs. 10.88 Rs. 0.62
  Discontinued operations Rs. 1.47
Net income Rs. 10.88 Rs. 2.09
Weighted average number of equity shares used in
computing earnings per equity share
   
Basic 372,595,730 372,216,805
Effect of dilutive securities-employee stock option 746,412 1,089,479
Diluted 373,342,142 373,306,284
The accompanying notes are an integral part of these consolidated financial statements.